

No difference in survival in patients intolerant to their last chemotherapy

- Fewer than 10% of patients were intolerant to their last chemotherapy in the ISEL trial.
- Amongst these patients there were actually more deaths in placebo treated patients compared to Iressa treated patients:
 - 45.8% (22/48) deaths on placebo compared 43.5% (50/115) deaths on Iressa
 - HR=0.99 (0.59, 1.65), p=0.97.
- Therefore, considering survival over the full follow-up period, there no difference in survival between Iressa and placebo in chemotherapy intolerant patients.

Within the patients who were intolerant of their prior chemotherapy, demography was well balanced at baseline

		All patients	
		Gefitinib N=115	Placebo N=48
Age (median)		64 years	65 years
Male		62%	58%
PS 0-1		70%	69%
Never smoked		23%	21%
2nd line		50%	48%
Adenocarcinoma histology		50%	38%
Time from diagnosis to randomisation	<6 months	26%	17%
	6-12 months	34%	23%
	> 12 months	40%	60%
Best response to prior chemotherapy	CR/PR	21%	38%
	SD	46%	44%
	PD/NE	33%	19%

Back up slides

Oriental patient data: Demography

		Gefitinib N=235	Placebo N=107
Age (median)		61 years	61 years
Male		60%	60%
PS 0-1		72%	72%
Never smoked		41%	41%
2 nd line		54%	65%
Histology	Adenocarcinoma	64%	64%
Time from diagnosis to randomisation	< 6 months	25%	32%
	6-12 months	40%	38%
Best response to prior chemotherapy	CR/PR	21%	21%
	SD	35%	32%
	PD/NE	44%	48%